Increased prevalence of diabetes mellitus in bullous pemphigoid patients during the last decade

Abstract

Bullous pemphigoid (BP) is a rare autoimmune blistering disease. The association between BP and diabetes mellitus (DM) has been previously reported with inconsistent results^1-4. Dipeptidyl peptidase (DPP)-IV inhibitors, approved in Europe by EMA in 2007 to treat type-2 DM, are antihyperglycemic drugs that could induce BP disease^5-9.

This article is protected by copyright. All rights reserved.